116 related articles for article (PubMed ID: 24911474)
1. Sovaldi makes blockbuster history, ignites drug pricing unrest.
Senior M
Nat Biotechnol; 2014 Jun; 32(6):501-2. PubMed ID: 24911474
[No Abstract] [Full Text] [Related]
2. Dare to refuse the exorbitant price of Sovaldi!
Prescrire Int; 2014 Nov; 23(154):278. PubMed ID: 25954802
[No Abstract] [Full Text] [Related]
3. Screening urged for hepatitis C but drug costs are prohibitive.
Fralick M
CMAJ; 2014 Mar; 186(5):329. PubMed ID: 24549123
[No Abstract] [Full Text] [Related]
4. Take a Bow, Pharma, for the Hepatitis C Drugs.
Reinke T
Manag Care; 2018 Apr; 27(4):12-13. PubMed ID: 29701579
[TBL] [Abstract][Full Text] [Related]
5. Sofosbuvir (Sovaldi) for hepatitis C virus.
Lomberk M; Klibanov OM
Nurse Pract; 2015 Sep; 40(9):16-9. PubMed ID: 26274882
[No Abstract] [Full Text] [Related]
6. Guideline: New HCV drugs should go to sickest patients.
Kuehn BM
JAMA; 2014 Sep; 312(11):1084-5. PubMed ID: 25226461
[No Abstract] [Full Text] [Related]
7. Sovaldi dilemma likely to get worse.
Carroll J
Manag Care; 2014 Sep; 23(9):9, 12. PubMed ID: 25282860
[No Abstract] [Full Text] [Related]
8. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.
Iyengar S; Tay-Teo K; Vogler S; Beyer P; Wiktor S; de Joncheere K; Hill S
PLoS Med; 2016 May; 13(5):e1002032. PubMed ID: 27243629
[TBL] [Abstract][Full Text] [Related]
9. Gilead injects own generics into shrinking HCV drug market.
Morrison C
Nat Biotechnol; 2018 Nov; 36(11):1030. PubMed ID: 30412188
[No Abstract] [Full Text] [Related]
10. US health insurers say Gilead hepatitis C drug too costly.
Clin Infect Dis; 2014 Jul; 59(2):i-ii. PubMed ID: 25105185
[No Abstract] [Full Text] [Related]
11. China rejects patent on hepatitis C drug sofosbuvir.
Kmietowicz Z
BMJ; 2015 Jun; 350():h3429. PubMed ID: 26105994
[No Abstract] [Full Text] [Related]
12. FDA approvals usher in the post-interferon era in HCV.
Sheridan C
Nat Biotechnol; 2014 Jan; 32(1):3-5. PubMed ID: 24406908
[No Abstract] [Full Text] [Related]
13. King of the pills.
Cohen J
Science; 2015 May; 348(6235):622-5. PubMed ID: 25953989
[No Abstract] [Full Text] [Related]
14. Hepatitis C drug maker puts profit ahead of patients, US Senate report charges.
McCarthy M
BMJ; 2015 Dec; 351():h6573. PubMed ID: 26635239
[No Abstract] [Full Text] [Related]
15. A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients.
Phelan M; Cook C
BMC Infect Dis; 2014; 14 Suppl 6(Suppl 6):S5. PubMed ID: 25253373
[No Abstract] [Full Text] [Related]
16. Commentary on "no to greed".
Hunt DP
South Med J; 2015 Jan; 108(1):65-6. PubMed ID: 25580762
[No Abstract] [Full Text] [Related]
17. Elimination on the agenda for hepatitis C.
Burki T
Lancet Infect Dis; 2014 Jun; 14(6):452-3. PubMed ID: 24971446
[No Abstract] [Full Text] [Related]
18. WHO issues guidelines on HCV amid drug cost controversy.
Slomski A
JAMA; 2014 Jun; 311(22):2262-3. PubMed ID: 24915242
[No Abstract] [Full Text] [Related]
19. Insurers brace for high-cost Sovaldi.
Demko P; Dickson V
Mod Healthc; 2014 May; 44(18):9. PubMed ID: 25033622
[No Abstract] [Full Text] [Related]
20. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.
Hill A; Khoo S; Fortunak J; Simmons B; Ford N
Clin Infect Dis; 2014 Apr; 58(7):928-36. PubMed ID: 24399087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
